CRYSVITA
Google image searchProduct monograph
Active ingredient
burosumab, 20 MG/ML
DIN: 02483637
Dosage form(s): SOLUTION
Route(s) of administration: SUBCUTANEOUS
Description: SINGLE USE VIAL
Schedule: Prescription / Schedule D
Company: KYOWA KIRIN, INC.
Date: 03-MAR-2023
ATC:
- M05 — DRUGS FOR TREATMENT OF BONE DISEASES (ATC, ATC/DDD, )
- M05B — DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION (ATC, ATC/DDD)
- M05BX — Other drugs affecting bone structure and mineralization (ATC, ATC/DDD)
- M05BX05 — BUROSUMAB (ATC/DDD)
Pharmaceutical standard: MFR
